Owen Mumford Acquires Empelvic

Owen Mumford

Owen Mumford, a global leader in innovative medical device solutions, has announced the acquisition of pelvic floor cushion brand Empelvic, bolstering the company’s pelvic and sexual health portfolio with accessible solutions designed to help consumers treat conditions at their own pace.

Treatment of Pelvic Issues

With more people becoming hesitant at seeing a doctor for intimate health conditions it suggests that they are looking to treat pelvic and sexual health conditions at home, therefore the need for accessible and user-friendly products that support at-home treatment has never been more important[i]. With over 70 years of experience developing medical devices and pioneering several world-first technologies, Owen Mumford is expanding its offering to provide a comprehensive range of products covering multiple therapeutic areas but connected by a guiding mission to reimagine consumers’ approaches to intimate health.

Empelvic Was Established in Denmark

Previously a winner of the ‘Healthy Life’ category in the 2020 Danish Design Awards, Empelvic was established in Denmark by Midwife Gry Senderovitz and Entrepreneur Michael Severinsen and exists to provide an accessible and easy way to connect with your pelvic floor and improve your pelvic health. A non-invasive device, the shape is ergonomically designed to connect with the pelvic floor – with individual shapes for men and women. When sat on, the cushion helps to increase awareness of the pelvic floor and makes it easier to connect with the individual pelvic muscles, helping to engage them to train their strength gently and without harm. The device also helps people to relax their pelvic floor, in turn helping to treat a hypertonic pelvic floor. The distinctive product, designed to both relax and strengthen, is paired with user-friendly support that teaches how to easily establish, maintain, and strengthen a pelvic floor connection, regardless of age or gender. Empelvic has been created to help treat conditions like stress incontinence, vaginismus and erectile dysfunction by training the pelvic floor muscles[ii].

“The acquisition of Empelvic reinforces our commitment to comprehensive health solutions for intimate conditions,” said Adam Mumford, Director of Medical Devices at Owen Mumford. “By combining Owen Mumford’s global expertise with Empelvic’s innovative product, we aim to provide enhanced support and choices for individuals seeking pelvic health solutions.”

With Empelvic originating from Denmark, this acquisition also brings with it an exciting expansion into the wider Scandinavian territories. Co-founder Gry Senderovitz noted; “As a company with roots in Denmark, this strategic move allows us to leverage Owen Mumford’s extensive reach and resources, ultimately enhancing our ability to serve individuals seeking pelvic health solutions in Scandinavia and beyond. We look forward to the positive impact this acquisition will have on the lives of many as we continue our mission to make a meaningful difference in pelvic health and well-being.”

Empelvic will join Owen Mumford’s existing pelvic and sexual health portfolio alongside its Amielle Comfort and Care vaginal dilators and the Rapport vacuum therapy device, empowering individuals to take control of their pelvic and sexual well-being.

For more information on Empelvic please visit: https://claritistore.de/

[i] Kingsberg SA, Schaffir J, Faught BM, Pinkerton JV, Parish SJ, Iglesia CB, Gudeman J, Krop J, Simon JA. Female Sexual Health: Barriers to Optimal Outcomes and a Roadmap for Improved Patient-Clinician Communications. J Womens Health (Larchmt). 2019 Apr;28(4):432-443. doi: 10.1089/jwh.2018.7352. Epub 2019 Feb 4. PMID: 30714849; PMCID: PMC6482896.

[ii] Yaacov D, Nelinger G, Kalichman L. The Effect of Pelvic Floor Rehabilitation on Males with Sexual Dysfunction: A Narrative Review. Sex Med Rev. 2022 Jan;10(1):162-167. doi: 10.1016/j.sxmr.2021.02.001. Epub 2021 Apr 27. PMID: 33931383.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”